MedPath

Resveratrol

Generic Name
Resveratrol
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C14H12O3
CAS Number
501-36-0
Unique Ingredient Identifier
Q369O8926L
Background

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.

Indication

Being investigated for the treatment of Herpes labialis infections (cold sores).

Associated Conditions
-
Associated Therapies
-

Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy

Phase 2
Completed
Conditions
Peripheral Diabetic Neuropathy
Interventions
Drug: Super Oxide Dismutase
Drug: Resveratrol, Alpha lipoic acid, Super oxide dismutase
Drug: Resveratrol
Drug: Alpha lipoic acid
First Posted Date
2023-11-14
Last Posted Date
2024-08-26
Lead Sponsor
Khyber Medical University Peshawar
Target Recruit Count
100
Registration Number
NCT06131918
Locations
🇵🇰

Syed Hamid Habib, Peshawar, KPK, Pakistan

Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency

Not Applicable
Conditions
Primary Ovarian Insufficiency
Interventions
First Posted Date
2022-06-08
Last Posted Date
2022-06-08
Lead Sponsor
Affiliated Hospital of Nantong University
Target Recruit Count
150
Registration Number
NCT05410093
Locations
🇨🇳

B ultrasound, Nantong, Jiangsu, China

Effect of Resveratrol and Pharmacist Intervention on Diabetes Mellitus and Its Neuropathic Complication

Not Applicable
Completed
Conditions
Diabetic Neuropathies
Interventions
Drug: Placebo
Other: Resveratrol plus Pharmaceutical care
Other: Placebo+Pharmaceutical care
Drug: Resveratrol
First Posted Date
2021-12-29
Last Posted Date
2023-03-14
Lead Sponsor
University of Sulaimani
Target Recruit Count
120
Registration Number
NCT05172947
Locations
🇮🇶

College of Pharmacy-University of Sulaimani, Sulaymānīyah, Iraq

The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients

Not Applicable
Conditions
Covid-19
Interventions
Drug: Placebo capsules
Drug: Resveratrol
First Posted Date
2021-03-16
Last Posted Date
2021-07-16
Lead Sponsor
Hong Kong Baptist University
Target Recruit Count
30
Registration Number
NCT04799743
Locations
🇭🇰

Linda Zhong, Kowloon Tong, Kowloon, Hong Kong

Nasal Resveratrol and Wheezing Episodes in Preschool Children

Completed
Conditions
Wheezing
Upper Respiratory Tract Infections
Interventions
First Posted Date
2020-12-30
Last Posted Date
2020-12-30
Lead Sponsor
University Of Perugia
Target Recruit Count
50
Registration Number
NCT04689412
Locations
🇮🇹

Università di Perugia, Perugia, Italy

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

Early Phase 1
Recruiting
Conditions
Type 1 Diabetes
Interventions
Drug: Resveratrol
Other: Placebo
First Posted Date
2020-06-26
Last Posted Date
2024-07-31
Lead Sponsor
Augusta University
Target Recruit Count
24
Registration Number
NCT04449198
Locations
🇺🇸

Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta, Georgia, United States

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

Phase 2
Terminated
Conditions
COVID-19
Interventions
Dietary Supplement: Vitamin D3
Drug: Resveratrol
First Posted Date
2020-05-26
Last Posted Date
2023-02-24
Lead Sponsor
Marvin McCreary, MD
Target Recruit Count
105
Registration Number
NCT04400890
Locations
🇺🇸

Mt Carmel HealthSystems, Columbus, Ohio, United States

Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis

Early Phase 1
Recruiting
Conditions
Cystic Fibrosis
Interventions
Drug: Resveratrol
Drug: NR
Dietary Supplement: Placebo
First Posted Date
2019-11-18
Last Posted Date
2024-04-26
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
36
Registration Number
NCT04166396
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Micronised Resveratrol as a Treatment for Friedreich Ataxia

Phase 2
Completed
Conditions
Friedreich Ataxia
Interventions
First Posted Date
2019-05-01
Last Posted Date
2024-05-22
Lead Sponsor
Murdoch Childrens Research Institute
Target Recruit Count
25
Registration Number
NCT03933163
Locations
🇦🇺

Royal North Shore Hospital, St Leonards, New South Wales, Australia

🇦🇺

University of Queensland Centre for Clinical Research, Herston, Queensland, Australia

🇦🇺

Royal Perth Hospital, Perth, Western Australia, Australia

and more 1 locations

Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

Phase 2
Terminated
Conditions
Pseudoachondroplasia
Interventions
Drug: resveratrol
Drug: Placebo
First Posted Date
2019-03-07
Last Posted Date
2022-12-09
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
6
Registration Number
NCT03866200
Locations
🇺🇸

University of Texas Health Science Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath